Clinically, high NOX4 and IL-8 correlate with poorer responses to anti-PD-L1 therapy, while dual inhibition of NOX4 (with GKT137831) and EGFR has shown enhanced tumor suppression in mouse xenograft models [322]. This evidence concerns the gene NOX4 and neoplasm.